FibroGen, Inc (FGEN): Price and Financial Metrics
FGEN Price/Volume Stats
| Current price | $1.05 | 52-week high | $19.47 |
| Prev. close | $1.02 | 52-week low | $0.33 |
| Day low | $0.98 | Volume | 258,247 |
| Day high | $1.06 | Avg. volume | 2,424,321 |
| 50-day MA | $1.80 | Dividend yield | N/A |
| 200-day MA | $1.25 | Market Cap | 103.71M |
FGEN Stock Price Chart Interactive Chart >
FibroGen, Inc (FGEN) Company Bio
Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.
Latest FGEN News From Around the Web
Below are the latest news stories about FIBROGEN INC that investors may wish to consider to help them evaluate FGEN as an investment opportunity.
FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call TranscriptFibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript November 6, 2023 FibroGen, Inc. beats earnings expectations. Reported EPS is $-0.52, expectations were $-0.68. Operator: Hello and welcome to the FibroGen’s Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator […] |
Q3 2023 FibroGen Inc Earnings CallQ3 2023 FibroGen Inc Earnings Call |
FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net RevenueStrong Roxadustat Volume Growth in China and Successful Cost Reduction Plan Boosts Performance |
FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
FibroGen Reports Third Quarter 2023 Financial ResultsTopline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia Robust roxadustat volume growth of 37% in ChinaStrong execution of cost reduction plan reaffirming cash runway into 2026 SAN FRANCI |
FGEN Price Returns
| 1-mo | -59.30% |
| 3-mo | 12.19% |
| 6-mo | 120.54% |
| 1-year | -93.72% |
| 3-year | -95.12% |
| 5-year | -97.83% |
| YTD | 18.47% |
| 2023 | -94.47% |
| 2022 | 13.62% |
| 2021 | -61.98% |
| 2020 | -13.52% |
| 2019 | -7.32% |
Continue Researching FGEN
Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...